Infinimmune Appoints Anthony Slavin, Ph.D., as Senior Vice President of Portfolio Strategy [Yahoo! Finance]
A Look At Kymera Therapeutics (KYMR) Valuation After Fast Track News And Gilead Collaboration Progress [Yahoo! Finance]
FDA Grants Fast Track Designation to Kymera Therapeutics, Inc. (KYMR)'s KT-621 for Eosinophilic Asthma [Yahoo! Finance]
Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma